Home PMWS News PMWS Research PMWS Forum PMWS Newsletter
PCVD.org Dansk
PCVD.org Fran?ais
PCVD.org Svenska
PCVD.org Nederlands
PCVD.org Espa?ol
PCVD.org English


This free resource is kindly supported by Merial, MLC/BPEX and PCVD.org.
    If you have a information you would like is to include in this section please email the details to us at:
pmws@thepigsite.com

Vaccination
Management
Disease Information
A PMWS update (Jake Waddilove)
ABOUT PMWS & PDNS
National Pork Board PMWS Fact Sheet
About PDNS (Jake Waddilive)
CEI Emerging Disease Notices: PMWS / PDNS
Conference and meetings archive
Case Histories
Yorkshire Farm, UK - Mike Muirhead - Final Update, June 2002
Mike Muirhead's case history of a Yorkshire farm with PMWS and PDNS.
 
East Anglia Farm, UK - Philip Richardson
This paper charts the course and effects of the disease on a single herd as well as highlighting the economic impact.
Photographs
Clinical signs
Photos of the clinical signs that are seen generally in pigs with PMWS and PDNS. Includes skin lesions, enlarged lymph glands, wasting and dead pigs.
 
Post mortem (1)
Photos of the signs that are seen in post-mortem samples of pigs with PMWS and PDNS. Includes interstitial pneumonia, secondary bacterial infection, enlarged lymph nodes, oedema and intra cytoplasmic inclusions
 
Post mortem (2)
More Photos of the signs that are seen in post-mortem samples of pigs with PMWS and PDNS.


PMWS 研究文档

发表于Friday, December 01, 2006: Vet Microbiol. 2006 Dec 9; [Epub ahead of print]
Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2.
Wang X, Jiang P, Li Y, Jiang W, Dong X.
Post-weaning multisystemic wating syndrome (PMWS) associated with PCV2 was one of the most costly diseases currently faced by the swine industry. In order to develop a vaccine to control this disease, we previously constructed a recombinant adenovirus expressing the capsid of PCV2. Here, we examined the protection of swine against PMWS by the recombinant adenovirus. Eighteen 32-day-old pigs were assigned to three groups each with six. Group 1 was vaccinated subcutaneously with rAd-Cap and boosted 2 weeks later. Thirty-seven days after first vaccination, Groups 1 and 2 were oronasally challenged with virulent PCV2 isolate, 4 and 7 days later, intramuscularly exposed to keyhole limpet hemocyanin (KLH). Group 3 remained unchallenged but with KLH. The results showed that high level of PCV2-specific ELISA antibody and neutralizing antibody could be induced at 37 days after first vaccination. After challenge, pigs in vaccinated group had no clearly clinical signs, although some of them had increased rectal temperatures (>/=40 degrees C) for short time. The pyrexic phase in vaccinated group was significantly lighter than that in challenge-control group (P<0.05). The relative daily weight gain in vaccinated-challenged group was similar to that in empty control group. But it was significantly high compared to the challenge-control group (P<0.05). Mean while the pathological lesions and virema presented in vaccinated group were milder than those in control group. It indicated that the recombinant adenovirus was able to confer significant protection against clinical disease and reduce pathogenic lesions induced by PCV2 challenge, even though it could not provide complete virological protection. The recombinant adenovirus might be an attractive candidate vaccine for preventing the disease associated with PCV2 infection.如果您想继续阅读本文，请点这里...

Have you published information? To add please email the details

pcvd Merial BPEX PMWS, PCVD Technical Zone home page

2010年 8月 1日 星期日

网站搜索